Sanguinarine inhibits osteoclast formation and bone resorption via suppressing RANKL-induced activation of NF-κB and ERK signaling pathways

► A natural-derived compound, sanguinarine, suppresses osteoclastic bone resorption. ► Sanguinarine inhibits the RANKL-induced osteoclast formation. ► Sanguinarine impairs the NF-κB and ERK pathways during osteoclastogenesis. ► Sanguinarine have therapeutic value in treating osteoclast-related oral diseases.